Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years
Last Updated: Wednesday, December 15, 2021
An age-based analysis of the FDA Adverse Events Reporting System (FAERS) database revealed differences in patterns of adverse events experienced by patients aged < 65 and ≥ 65 treated with axicabtagene ciloleucel and tisagenlecleucel.
Advertisement
News & Literature Highlights